Analysis finds most approved cancer medicines in Europe deliver limited benefit
A new analysis of cancer treatments approved by European regulators found that most recent approvals did not deliver high clinical benefit. The study examined 97 indications for 63 cancer treatments approved from January 2022 through July 2026 and concluded…
